The Europe irritable bowel syndrome (IBS) diagnostics market is expected to reach US$ 1,191.44 million in 2028 from US$ 776.26 million in 2020; it is estimated to grow with a CAGR of 5.6% from 2020 to 2028. The growth of the market is attributed to the factors such as increasing prevalence of irritable bowel syndrome and associated conditions and advancements in diagnostics of syndrome. On the other hand, challenges in diagnosis of IBS are likely to restraint the growth of market during the forecast years.
Irritable bowel syndrome is a chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. People across the world are witnessing considerable incidence of irritable bowel syndrome. Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are among the risk factors that cause irritable bowel syndrome. According to IBS Global Impact Report, in 2016, an estimated mean prevalence of Irritable Bowel Syndrome ranged to 1.1 % in France. Such staggering prevalence of irritable bowel syndrome is likely to boost the irritable bowel syndrome (IBS) diagnostics market during the forecast period. To cope up against irritable bowel syndrome, the companies involved in the drug development for irritable bowel syndrome are taking constructive steps to create awareness programs with an aim to spread awareness amongst the population. Such initiatives are anticipated to drive the growth of the irritable bowel syndrome (IBS) diagnostics market. Also, increasing number of FDA approvals and diagnostics development activities are likely to accelerate the growth of the irritable bowel syndrome (IBS) diagnostics market during the forecast period.
With the spread of the COVID-19 pandemic, it is discovered that a significant number of people across the world are suffering from irritable bowel syndrome (IBS), as COVID-19 pandemic has affected the psychological health of people, resulting in a higher level of stress. Stress can exaggerate the symptoms of irritable bowel syndrome (IBS). Thus, the impact of COVID-19 is so far considered positive on the market. Therefore, the growing demand for irritable bowel syndrome (IBS) diagnostics in Europe is likely to boost the growth of the irritable bowel syndrome (IBS) diagnostics market.
Based on the diagnosis, the Europe irritable bowel syndrome (IBS) diagnostics market was segmented into laboratory tests and imaging tests. In 2020, the laboratory tests segment held a larger share of the market and is expected to grow at a faster rate during the coming years.
Based on indication, the Europe irritable bowel syndrome (IBS) diagnostics market is segmented into pain and cramping, diarrhea, constipation, and alternating constipation & diarrhea. The pain and cramping segment held the largest share of the market in 2020 and is anticipated to register the highest CAGR in the market during the forecast period.
A few of the primary and secondary sources associated with this report on the Europe irritable bowel syndrome (IBS) diagnostics market are European Union (EU), Centers for Disease Control and Prevention (CDC) and International Foundation for Gastrointestinal Disorders (IFFGD).
Reasons to Buy
With the spread of the COVID-19 pandemic, it is discovered that a significant number of people across the world are suffering from irritable bowel syndrome (IBS), as COVID-19 pandemic has affected the psychological health of people, resulting in a higher level of stress. Stress can exaggerate the symptoms of irritable bowel syndrome (IBS). Thus, the impact of COVID-19 is so far considered positive on the market. Therefore, the growing demand for irritable bowel syndrome (IBS) diagnostics in Europe is likely to boost the growth of the irritable bowel syndrome (IBS) diagnostics market.
Based on the diagnosis, the Europe irritable bowel syndrome (IBS) diagnostics market was segmented into laboratory tests and imaging tests. In 2020, the laboratory tests segment held a larger share of the market and is expected to grow at a faster rate during the coming years.
Based on indication, the Europe irritable bowel syndrome (IBS) diagnostics market is segmented into pain and cramping, diarrhea, constipation, and alternating constipation & diarrhea. The pain and cramping segment held the largest share of the market in 2020 and is anticipated to register the highest CAGR in the market during the forecast period.
A few of the primary and secondary sources associated with this report on the Europe irritable bowel syndrome (IBS) diagnostics market are European Union (EU), Centers for Disease Control and Prevention (CDC) and International Foundation for Gastrointestinal Disorders (IFFGD).
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe irritable bowel syndrome (ibs) diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe irritable bowel syndrome (ibs) diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Irritable Bowel Syndrome (IBS) Diagnostics Market- Market Landscape
5. Irritable Bowel Syndrome (IBS) Diagnostics Market - Key Market Dynamics
6. Irritable Bowel Syndrome (IBS) Diagnostics Market- Europe Analysis
7. Irritable Bowel Syndrome (IBS) Diagnostics Market Analysis- by Diagnosis
8. Irritable Bowel Syndrome (IBS) Diagnostics Market Analysis - By Indication
9. Irritable Bowel Syndrome (IBS) Diagnostics Market Analysis and Forecasts To 2028 - Europe Analysis
10. Impact of COVID-19 Pandemic on Europe Irritable Bowel Syndrome (IBS) Diagnostics Market
11. Irritable Bowel Syndrome (IBS) Diagnostics Market- Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Commonwealth Diagnostics International
- Genova Diagnostics
- Inova Diagnostics, Inc.
- Biohit Oyj
- Aerodiagnostics, LLC.
- Sysmex Corporation (Sysmex Europe GmbH)
- BÜHLMANN Laboratories AG
Table Information
| Report Attribute | Details |
|---|---|
| Published | May 2021 |
| Forecast Period | 2020 - 2028 |
| Estimated Market Value ( USD | $ 776.26 Million |
| Forecasted Market Value ( USD | $ 1191.44 Million |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Europe |
